Research Article
Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma
Table 1
Patient characteristics and responses to mogamulizumab multimodality therapy.
| | Age at start of mogamulizumab | Median (range) | 72 (45–86) |
| | Sex, N (%) | Male | 11 (58) | | Female | 8 (42) |
| | Race, N (%) | White | 17 (89) | | Black | 2 (11) |
| | CTCL subtype, N (%) | Mycosis fungoides | 2 (11) | | Sezary syndrome | 17 (89) |
| | Stage at start of mogamulizumab, N (%) | IB | 2 (11) | | IIIA | 1 (5) | | IIIB | 3 (16) | | IVA1 | 10 (53) | | IVA2 | 3 (16) |
| | Number of systemic therapies prior to mogamulizumab | Median (range) | 4 (0–7) |
| | Systemic treatment prior to mogamulizumab | No prior systemic treatment | 3 (16) | | Pembrolizumab | 2 (11) | | Multimodality regimen of ECP, interferon, and/or bexarotene (without mogamulizumab) | 14 (74) |
| | Response to prior systemic treatment regimen, N (%) | | CR | PR | SD | PD | Unknown | No prior treatment | | Best response | 3 (23) | 7 (54) | 2 (15) | 1 (8) | 3 | 3 | | Response immediately prior to mogamulizumab | — | 2 (14) | 2 (14) | 10 (72) | 2 | 3 |
| | Mogamulizumab timing, N (%) | Mogamulizumab added to prior multimodality regimen | 14 (74) | | | | | | | Mogamulizumab monotherapy followed by multimodality therapy | 5 (26) | | | | | |
| | Therapies included in mogamulizumab combination regimens, N (%) | Bexarotene | 9 (47) | | | | | | | Isotretinoin | 1 (5) | | | | | | | Extracorporeal photopheresis | 14 (74) | | | | | | | Interferon-alpha | 11 (58) | | | | | | | Interferon-gamma | 7 (37) | | | | | |
| | Best response to mogamulizumab combination therapy, N (%) | | CR | PR | SD | PD | Unknown | Uninvolved | | (i) Global (N = 16) | 9 (56) | 7 (44) | — | — | 3 | — | | (ii) Skin (N = 18) | 9 (50) | 7 (39) | 2 (11) | — | — | 1 | | (iii) Blood (N = 15) | 13 (87) | 1 (7) | 1 (7) | — | 1 | 3 | | (iv) Lymph nodes (N = 7) | 5 (71) | — | 2 (29) | | 3 | 9 | | (v) Viscera (N = 0) | — | — | — | — | — | 19 |
| | Best global response by disease subtype, N (%) | (i) MF (N = 2) | 1 (50) | 1 (50) | — | — | — | — | | (ii) SS (N = 17) | 8 (57) | 6 (43) | — | — | 3 | — |
| | Duration of response, months | Median (range) | Not yet reached |
| | Progression-free survival, months | Median (range) | Not yet reached |
|
|
